Nektar Builds Case For Irinotecan-Inspired NKTR-102 In Cancer

Company’s R&D day stresses areas of unmet need for NKTR-102 in metastatic breast cancer. Company also highlights data from a Phase II study showing the drug’s promise in high-grade brain cancer.